摘要
目的:研究糖脉交泰胶囊对db/db 2型糖尿病小鼠糖脂代谢的作用与机制。方法:随机将db/db 2型糖尿病小鼠分为模型组、糖脉交泰组(1.1g/kg)和吡格列酮组(4mg/kg),每组8只,给予相应的药物治疗4周。实验结束后比较各组空腹血糖值(FBG)、糖化血清蛋白(GSP)、糖化血红蛋白(HbA1c)、血清总胆固醇(TC)、甘油三脂(TG)等糖脂代谢指标,比较各组血清胰岛素(INS)浓度及胰岛素抵抗指数、胰岛素敏感指数、超氧化物歧化酶活性(SOD)、丙二醛含量(MDA)等变化,检测各组肝脏组织中肝糖原含量及葡萄糖激酶蛋白(GCK)和低密度脂蛋白受体(LDLR)等蛋白表达。结果:与模型组比较,糖脉交泰胶囊(1.1g/kg)能显著降低大鼠FBG、GSP、HbA1c、TC、TG等指标的升高(P<0.05),明显改善INS水平及胰岛素抵抗指数、胰岛素敏感指数,SOD、MDA等指标的异常(P<0.05);显著提高肝脏中肝糖原含量、GCK及LDLR的蛋白表达(P<0.05)。结论:糖脉交泰胶囊(1.1g/kg)具有明显改善糖脂代谢紊乱的作用,其作用机制与其改善胰岛素抵抗、提高肝脏GCK蛋白表达与肝糖原含量、提高肝脏LDLR蛋白表达等密切相关。
Objective:The aim of the current study was to investigate the effect and mechanism of TangMaiJiaoTai on glucose and lipid metabolism in C57BL/KSJ-db/db mice.Methods:Male C57BL/KsJ-db/db(db/db) mice were randomly divided into diabetes,TMJT(1.1g/kg) and pioglitazone(4mg/kg) groups(n=8).Each group was given the corresponding treatment for 4 weeks.Parameters related to glycolipid metabolism including fasting blood glucose(FBG),glycosylated serum protein(GSP),glycosylated hemoglobin(HbA1c),serum total cholesterol(TC) and triglycerides(TG) were measured and compared among groups at the end of the experiment.Meanwhile,plasma insulin,insulin resistance index(IR),quantitative insulin sensitivity check index(QUICKI),superoxide dismutase activity(SOD) and malondialdehyde content(MDA) were tested.Western blotting assay was applied to detect the protein expression of glucokinase(GCK) and low-density lipoprotein receptor(LDLR).Results:TangMaiJiaoTai(1.1g/kg) significantly attenuated the abnormal increase of FBG,GSP,HbA1c,TC and TG in serum of db/db mice(P0.05).The level of plasma insulin,glucose tolerance,SOD and MDA were improved by TangMaiJiaoTai treatment(P0.05).Furthermore,the liver glycogen content and protein expression of GCK and LDLR in liver were markedly increased in db/db mice after TangMaiJiaoTai treatment(P0.05).Conclusions:These results suggest that TangMaiJiaoTai(1.1g/kg) has obvious effect on regulating the disturbance of glucose and lipid metabolism.This function of TangMaiJiaoTai is relevant to its role in regulating insulin resistance and improving the content of liver glycogen and protein levels of GCK and LDLR.
出处
《中药药理与临床》
CAS
CSCD
北大核心
2012年第5期177-180,共4页
Pharmacology and Clinics of Chinese Materia Medica
基金
粤港关健领域重点突破招标项目
编号:2008A03060008
广东省重大科技专项(重大新药创制)计划项目
编号:2011A080502004
广州市科技计划项目
编号:10A32060084